[1] Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.
[2] Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer[J]. JAMA Oncol, 2018, 4(3): 374-378.
[3] Müller Ⅴ, Oliveira-Ferrer L, Steinbach B, et al. Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer[J]. Mol Oncol, 2019, 13(5): 1137-1149.
[4] Mansoori Y, Zendehbad Z, Askari A, et al. Breast cancer-linked lncRNA u-eleanor is upregulated in breast of healthy women with lack or short duration of breastfeeding[J]. J Cell Biochem, 2019, 120(6): 9869-9876.
[5] Cao J, Dong R, Jiang L, et al. LncRNA-MM2P identified as a modulator of macrophage M2 polarization [J]. Cancer Immunol Res, 2019, 7(2): 292-305.
[6] Zhou Y, He P, Xie X, et al. Knockdown of SUMO1P3 represses tumor growth and invasion and enhances radiosensitivity in hepatocellular carcinoma[J]. Mol Cell Biochem, 2019, 450(12): 125-134.
[7] Lin H, Guo Q, Lu S, et al. LncRNA SUMO1P3 promotes proliferation and inhibits apoptosis in colorectal cancer by epigenetically silencing CPEB3[J]. Biochem Biophys Res Commun, 2019, 511(2): 239-245.
[8] Tian C, Jin Y, Shi S. Long noncoding RNA SUMO1P3 may promote cell proliferation, migration, and invasion of pancreatic cancer via EMT signaling pathway[J]. Oncol Lett, 2018, 16(5): 6109-6115.
[9] Zhang Y, Li Y, Han L, et al. SUMO1P3 is associated clinical progression and facilitates cell migration and invasion through regulating miR-136 in nonsmall cell lung cancer[J]. Biomed Pharmacother, 2019, 113(5): 108686-108692.
[10] Zhang X, Wu N, Wang J, et al. LncRNA MEG3 inhibits cell proliferation and induces apoptosis in laryngeal cancer via miR-23a/APAF-1 axis[J]. J Cell Mol Med 2019, 23(10): 6708-6719.
[11] Yang Y, Lv X, Fan Q, et al. Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: differential expression profile of circulating lncRNA[J]. Clin Nephrol, 2019, 92(1): 25-35.
[12] Zhou J, Zhou Y, Wang C. LncRNA-MIAT regulates fibrosis in hypertrophic cardiomyopathy (HCM) by mediating the expression of miR-29a-3p[J]. J Cell Biochem, 2019, 120(5): 7265-7275.
[13] Yang J, Meng X, Yu Y, et al. LncRNA POU3F3 promotes proliferation and inhibits apoptosis of cancer cells in triple-negative breast cancer by inactivating caspase 9[J]. Biosci Biotechnol Biochem, 2019, 83(6): 1117-1123.
[14] Liu J, Song Z, Feng C, et al. The long non-coding RNA SUMO1P3 facilitates breast cancer progression by negatively regulating miR-320a [J]. Am J Transl Res, 2017,9(12):5594-5602.
[15] Zhan Y, Liu Y, Wang C, et al. Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer[J]. Oncotarget, 2016, 7(13): 16038-16048.
[16] Wu S, Chen S, Lin N, et al. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a[J]. J Cell Mol Med, 2020, 24(5):3108-3116.
[17] Zhou LL, Wang RT, Zhao Y, et al. Effects of picropodophyllin on proliferation and cell cycle of human colorectal cancer HCT-15 cells and its mechanism [J]. Acta Anatomica Sinica, 2020,51 (2): 233-238.(in Chinese)
周丽丽,王瑞婷,赵杨,等. 鬼臼苦素对人结直肠癌HCT-15细胞增殖和周期的影响及其作用机制[J].解剖学报,2020,51(2):233-238.
[18] Wang S, Wang X, Gao Y, et al. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway[J]. J Pathol, 2019, 248(2): 204-216.
[19] Patel P, Tsiperson V, Gottesman SRS, et al. Dual inhibition of CDK4 and CDK2 via targeting p27 tyrosine phosphorylation induces a potent and durable response in breast cancer cells [J]. Mol Cancer Res, 2018, 16(3): 361-377.
[20] Zhou M, Liu X, Li Z, et al. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells[J]. Int J Cancer, 2018, 143(4): 921-930.
[21] Zhang C, Li C, Wang Y, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation[J]. Apoptosis, 2019, 24 (34): 312-325.
[22] Zhong JL, Zheng L, He H, et al. Advances in research on biological regulation mechanisms related to PI3K/Akt signaling pathway [J]. Genomics and Applied Biology, 2019, 38 (1): 143-147.(in Chinese)
钟佳琳, 郑立, 贺花, 等. PI3K/Akt 信号通路相关的生物学调控机制研究进展[J]. 基因组学与应用生物学, 2019,38 (1): 143-147.
[23] Zarate YA, Boccuto L, Srikanth S, et al. Constitutive activation of the PI3K-Akt pathway and cardiovascular abnormalities in an individual with Kosaki overgrowth syndrome[J]. Am J Med Genet A, 2019, 179(6): 1047-1052.
[24] Tian X, Ji Y, Liang Y, et al. LINC00520 targeting miR-27b-3p regulates OSMR expression level to promote acute kidney injury development through the PI3K/Akt signaling pathway [J]. J Cell Physiol, 2019, 234(8): 14221-14233.
[25] Khan MI, Hamid A, Rath S, et al. Akt inhibition modulates H3K4 demethylase levels in pten-null prostate concer[J]. Mol Cancer Ther, 2019, 18(2): 356-363.
[26] Karlsson E, Veenstra C, G?rsj? J, et al. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer[J]. J Cancer Res Clin Oncol, 2019, 145(3): 599-607.
|